Heat Biologics Stock News

'Directors and management of HS companies, B&V and brokers were the only people to make money from the HS schemes.'

Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2020 Earnings Conference Call May 8, 2020 08:00 AM ET Company Participants Sarah Carmody – Executive Director-Invest

(EDGAR Online via COMTEX) -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Note Regarding Forward-Looking Statements...

Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update

Novartis AG on Wednesday received the U.S. Food and Drug Administration's approval for its drug to treat patients with a tough-to-treat form of lung cancer, the drugmaker said.

A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel...

Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs.

Genprex issues a letter to shareholders, providing corporate and clinical updates.

Following the current crisis, healthcare stocks have been getting more attention. The reason is simple: More spending will go to healthcare, particularly biotec

- Not intended for US-, Canada- or UK-based media

DURHAM, NC / ACCESSWIRE / April 29, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic and prophylactic vaccin

Amarillo Biosciences (OTCMKTS:AMAR) and Heat Biologics (NASDAQ:HTBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength